Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The FACTOR Study (Filanesib and Carfilzomib Treatment of Relapsed/Refractory Multiple Myeloma):A Multinational, Randomized, Open-label Phase 3 Study of Filanesib (ARRY-520) + Carfilzomib Versus Single-agent Carfilzomib in Patients With Advanced Multiple Myeloma

Next Previous
Search
Trial Profile

The FACTOR Study (Filanesib and Carfilzomib Treatment of Relapsed/Refractory Multiple Myeloma):A Multinational, Randomized, Open-label Phase 3 Study of Filanesib (ARRY-520) + Carfilzomib Versus Single-agent Carfilzomib in Patients With Advanced Multiple Myeloma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filanesib (Primary) ; Carfilzomib
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms FACTOR
  • Sponsors Array BioPharma

    • Most Recent Events

    • 03 Feb 2015 According to Array Biopharma media release, the company is delaying the start of patient enrollment until the binimetinib and encorafenib transactions with Novartis are closed.
    • 08 Nov 2014 New source identified and integrated (European Clinical Trials Database record: EudraCT2014-001052-39)
    • 25 Mar 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top